Factory directly supply N-Methyl-4-Chloropyridine-2-Carboxamide - 1-Phenyl-1,2,3,4-Tetrahydroisoquinoline CAS 22990-19-8 Assay ≥98.5% (HPLC) Solifenacin Succinate Intermediate Factory – Ruifu

Commercial Supply Solifenacin Succinate Related Intermediates: Solifenacin Succinate CAS: 242478-38-2 (R)-(-)-3-Quinuclidinol CAS: 25333-42-0 (S)-(+)-3-Quinuclidinol CAS: 34583-34-1 3-Quinuclidinone Hydrochloride CAS: 1193-65-3 1-Phenyl-1,2,3,4-Tetrahydro-Isoquinoline CAS: 22990-19-8 (S)-1-Phenyl-1,2,3,4-Tetrahydroisoquinoline CAS: 118864-75-8

Chemical Name	1-Phenyl-1,2,3,4-Tetrahydroisoquinoline
Synonyms	1,2,3,4-Tetrahydro-1-Phenylisoquinoline
CAS Number	22990-19-8
CAT Number	RF-PI155
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C15H15N
Molecular Weight	209.29
Brand	Ruifu Chemical

Item	Specifications
Appearance	White Crystal Powder
Single Impurity	≤0.20%
Melting Point	93.0~99.0℃
Loss on Drying	≤0.50%
Assay	≥98.5% (HPLC)
Assay	98.5%~101.0% (on the dried basis)
Test Standard	Enterprise Standard
Usage	Solifenacin Succinate (CAS: 242478-38-2) Intermediate

Package: Bottle, Aluminium foil bag, Cardboard Drum, 25kg/Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation. Solifenacin Succinate (CAS: 242478-38-2) is an antimuscarinic medication that is used to treat an overactive bladder causing symptoms of frequency, urgency, or incontinence. Solifenacin Succinate (CAS: 242478-38-2) is an M3 muscarinic receptor antagonist that was developed and launched for the treatment of overactive bladder (pollakiuria) in Europe. The synthesis of solifenacin involves the preparation of racemic 1-Phenyl-1,2,3,4-Tetrahydroisoquinoline via cyclization of N-(2-phenylethyl)benzamide, and subsequent reaction with ethyl chloroformate and transesterification with (R)- 3-Quinuclidinol. Chiral chromatography affords the isolation of the desired diastereomer. Alternatively, 1-Phenyl-1,2,3,4-Tetrahydroisoquinoline may be subjected to optical resolution with (+)-Tartaric Acid prior to treatment with ethyl chloroformate and subsequent transesterification.